Skip to main content

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

Feedback
Newsletter
RSS
Twitter

User Top Menu

Welcome, guest
Log In
Join
Why Join?

Search form

Search

About Us
- Overview
- Who We Are
- Contact
- Fan Mail
- How to Cite
News & Future Directions
Papers
Forums
- Discussions
- Webinars
Professional Resources
Research Resources
Click Here to Support MSDF

You are here

Home » Papers » Dilantin

Papers

Editors' Picks
Classic Papers
Archive

Dilantin

National Multiple Sclerosis Society

Accessed on 7 May 2014 from http://www.nationalmssociety.org/Treating-MS/Medications/Dilantin.

Comment
Recommend
Bookmark
Watch

Most Popular Papers

Viewed
Commented On
E-Mailed

In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination.

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.

Commentary: Outcome measures were flawed.

Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with COPAXONE(R)

Sanofi's history

Commentary: Outcome measures were flawed.

E-mail statistics unavailable.

Search Papers Archive

Words in title / abstract

Author

Journal

Keyword

Comment by

Papers by the week

Posting date

From

To

MSDF Footer

Copyright © 2014 MGH and ACP

Privacy
Terms of Use
How to Cite
FAQ/Help
Site Map
Support Us
Feedback
Image Credits

All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material.

Content By

Software By